Cardiac Marker Testing Market by Product, Biomarker, Type of Testing, Disease

List of Tables

[199 Pages Report] The Cardiac Marker Testing Market size was estimated at USD 5.10 billion in 2023 and expected to reach USD 5.50 billion in 2024, at a CAGR 7.90% to reach USD 8.69 billion by 2030.

Cardiac marker testing market consists of the spectrum of medical technologies and services that revolve around the usage of biomarkers for the diagnosis and management of cardiovascular diseases. The prevalence of cardiovascular diseases and need for effective diagnostics has increased the adoption of cardiac markers worldwide. The rise of point-of-care testing for cardiac markers has significantly increased the screening of cardiovascular diseases. The initiatives encouraging early cardiovascular disease detection have also contributed to market growth. However, the incidences of product recalls of cardiac marker testing solutions may limit its market adoption. The concerns associated with inaccuracy and limited specificity of cardiac market testing are also challenging factors for the market growth. Moreover, the advancements in testing technologies and the integration of new biomarkers are creating attractive opportunities in the market. Increasing consumer preference towards personalized medicine and the introduction of tailored cardiac marker testing are expected to witness significant growth in upcoming years.

KEY MARKET STATISTICS
Base Year [2023]	USD 5.10 billion
Estimated Year [2024]	USD 5.50 billion
Forecast Year [2030]	USD 8.69 billion
CAGR (%)	7.90%

Product: Significance of diagnostic instruments in cardiac marker testing

Diagnostic instruments in cardiac marker testing includes immunoassay analyzers, point of care (POC) devices, and chemiluminescence analyzers utilized to monitor and measure cardiac markers corresponding to heart conditions. Diagnostic instruments offer essential data evaluation for cardiac tests in a highly accurate, timely, and user-friendly manner. Reagents & kits are chemical solutions used for the proper functioning of instruments and the successful execution of cardiac marker testing procedures. Reagents & kits are vital in reacting with the biological samples, thereby helping to detect cardiac markers for various cardiac conditions.

Biomarker: Rising utilization of Troponin biomarker for cardiac assessment

Natriuretic peptides such as N-terminal proBNP (NT-proBNP) and B-type Natriuretic Peptide (BNP) are essential in the evaluation of heart failure, helping clinicians on cardiac disease management. Though CK-MB, a Creatine Kinase-MB isoenzyme, has been used in periprocedural myocardial infarction testings to better diagnose cardiac condition. High-sensitivity C-reactive protein (hs-CRP) testing is particularly advantageous for identifying low-grade inflammation to assess the risk of cardiovascular disease and stroke. Myoglobin is also a significant cardiac biomarker, favored for its very early peak (1 to 3 hours) following myocardial injury, primarily beneficial in the early detection of myocardial infarction. Troponin tests are currently the standard of care for diagnosing acute myocardial infarction due to their superior sensitivity and specificity.

Type of Testing: Increasing adoption of Point-of-Care testing

Laboratory testing involves analyzing patient samples in controlled lab environments, usually within hospitals or diagnostic centers, and utilizes advanced equipment for utmost accuracy. The high sensitivity and specificity of cardiac marker tests make it the preferred choice when precise results are mandatory in laboratory settings. Point-of-Care Testing (POCT) delivers rapid results in close proximity to the patient's location and are crucial in emergency cardiac conditions, facilitating real-time, actionable decisions that can significantly impact patient outcomes in cardiac disease conditions.

Disease: Extensive applications of cardiac marker testing in myocardial infarction

B-type Natriuretic Peptide (BNP) and N-terminal pro b-type Natriuretic Peptide (NT-proBNP) testing are used as primary cardiac marker tests for congestive heart failure due to their ability to prompt and accurate detection of symptoms. Myocardial infarction condition is effectively analyzed by cardiac marker tests such as troponin tests as troponin T and I levels in the blood increases after heart muscle damage.

Regional Insights

In the Americas region, the cardiac marker testing market has been flourishing with advancements in technology and the escalating prevalence of cardiovascular diseases. Several local companies and start-ups in major countries such as the United States, Canada, and Brazil, have been focusing on developing and introducing cost-effective and portable devices for effective cardiac assessment. In the Europe region, the cardiac marker testing market has been extensively driven by the increasing number of cardiovascular diseases, the aging population, and the well-established healthcare infrastructure. The cardiac marker testing market in the Middle East and Africa has been significantly impacted due to the rising awareness about coronary people diseases and the expansion of healthcare services. Cardiac marker testing market has been growing at an accelerated rate in APAC countries including China, India, and Japan due to the surge in healthcare services and the significant presence of major companies. The government support in terms of investments for healthcare research and development has led to an increase in innovations in cardiac testing methods.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cardiac Marker Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cardiac Marker Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cardiac Marker Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Assure Tech (Hangzhou) Co., Ltd., Atlas Medical GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Biomerieux SA, Boditech Med Inc., Charles River Laboratories International, Inc., Cleerly, Inc., Danaher Corporation, DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffmann-La Roche AG, HyTest Ltd., Laboratory Corporation of America Holdings, LightDeck Diagnostics, Merck KGaA, Natera, Inc., PerkinElmer Inc., Qiagen N.V., Quest Diagnostics, QuidelOrtho Corporation, Randox Laboratories Ltd., Sekbio, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corporation.

Market Segmentation & Coverage

This research report categorizes the Cardiac Marker Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- Instruments
  - Chemiluminescence
  - ELISA
  - Immunochromatography
  - Immunofluorescence

Reagents & Kits

Biomarker
- BNP Or NT-ProBNP
- Ceratine Kinase-MB
- hs-CRP
- Myoglobin
- Troponin

Type of Testing
- Laboratory Testing
- Point-Of-Care Testing

Disease
- Congestive Heart Failure
- Myocardial Infarction

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cardiac Marker Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cardiac Marker Testing Market?

3. What are the technology trends and regulatory frameworks in the Cardiac Marker Testing Market?

4. What is the market share of the leading vendors in the Cardiac Marker Testing Market?

5. Which modes and strategic moves are suitable for entering the Cardiac Marker Testing Market?

Product Code: MRR-034230D3E2E7

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cardiovascular diseases and need for effective diagnostics
  - 5.1.1.2. Rise of point-of-care testing for cardiac markers worldwide
  - 5.1.1.3. Initiatives encouraging early detection and screening of cardiovascular diseases
- 5.1.2. Restraints
  - 5.1.2.1. Adverse recalls of cardiac marker testing products
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in testing technologies and integration of new biomarkers
  - 5.1.3.2. Shift toward personalized medicine and introduction of tailored cardiac marker testing
- 5.1.4. Challenges
  - 5.1.4.1. Concerns associated with inaccuracy and limited specificity of cardiac marker testing
5.2. Market Segmentation Analysis
- 5.2.1. Product: Significance of diagnostic instruments in cardiac marker testing
- 5.2.2. Biomarker: Rising utilization of Troponin biomarker for cardiac assessment
- 5.2.3. Type of Testing: Increasing adoption of Point-of-Care testing
- 5.2.4. Disease: Extensive applications of cardiac marker testing in myocardial infarction
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Cardiac Marker Testing Market, by Product

6.1. Introduction
6.2. Instruments
6.3. Reagents & Kits

7. Cardiac Marker Testing Market, by Biomarker

7.1. Introduction
7.2. BNP Or NT-ProBNP
7.3. Ceratine Kinase-MB
7.4. hs-CRP
7.5. Myoglobin
7.6. Troponin

8. Cardiac Marker Testing Market, by Type of Testing

8.1. Introduction
8.2. Laboratory Testing
8.3. Point-Of-Care Testing

9. Cardiac Marker Testing Market, by Disease

9.1. Introduction
9.2. Congestive Heart Failure
9.3. Myocardial Infarction

10. Americas Cardiac Marker Testing Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cardiac Marker Testing Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cardiac Marker Testing Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Mindray Expands Cardiac Biomarker Portfolio with Launch of New Assays
- 13.3.2. NOWDx and AeenaDx Announce Merger
- 13.3.3. Pathkind Labs, Roche Diagnostics Partner to Release Cardiac Biomarker
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio